SequelSEC

Passage BIO, Inc. PASG

Biological Products, (No Diagnostic Substances) · CIK 0001787297 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2026-06-30
Operating income
-$8.27M
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

Passage BIO, Inc. (PASG) reported net income of -$7.82M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Passage BIO, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

Passage BIO, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
RevenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$8.27M-$8.25M-$13.85M-$8.66M-$10.33M-$16.46M-$14.27M-$20.70M-$17.38M-$18.05M
Net income-$7.82M-$7.56M-$12.98M-$7.75M-$9.38M-$15.40M-$12.72M-$19.34M-$15.99M-$16.71M
Research & development$3.34M$4.09M$5.42M$4.31M$5.81M$7.74M$9.56M$8.66M$10.43M$11.54M
Weighted-average diluted sharesshares 3.21Mshares 3.21MUnavailableshares 3.18Mshares 3.17Mshares 3.16MUnavailableshares 3.15Mshares 3.14Mshares 56.30M
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expenseUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Diluted EPS$-2.44$-2.36Unavailable$-2.44$-2.96$-4.87Unavailable$-6.15$-5.09$-0.30
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$6.87M$4.79M$4.92M$4.35M$4.52M$6.08M$4.71M$7.25M$6.51M$6.52M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Passage BIO, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Cash & equivalents$24.16M$33.34M$46.30M$52.77M$57.63M$63.36M$37.57M$32.29M$24.77M$36.77M
Total assets$25.18M$36.46M$62.28M$74.16M$79.20M$86.01M$102.41M$111.75M$125.39M$140.53M
Current assets$25.18M$34.74M$47.76M$55.73M$60.32M$66.67M$78.82M$87.22M$95.00M$108.29M
Total liabilities$20.72M$24.71M$43.53M$43.04M$40.94M$39.30M$41.15M$39.04M$34.84M$35.65M
Current liabilities$20.72M$20.10M$23.08M$22.24M$19.80M$17.82M$19.36M$16.95M$12.38M$12.84M
Total equity incl. NCI$4.46M$11.75M$18.76M$31.12M$38.26M$46.71M$61.26M$72.72M$90.56M$104.88M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$902.00K$1.31M$1.11M$952.00K$2.40M$1.46M$742.00K$1.49M$621.00K$1.69M

Cash flow

Passage BIO, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Operating cash flow-$9.18M-$12.99M-$6.48M-$4.85M-$6.33M-$13.85M-$8.44M-$7.45M-$13.14M-$18.93M
Capital expendituresUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Investing cash flow$0$20.00K$0$0$585.00K$39.63M$13.68M$14.97M$1.05M$25.25M
Financing cash flowUnavailableUnavailable$9.00K$0UnavailableUnavailable$47.00K$0$85.00K$8.74M
Net change in cash-$9.18M-$12.97M-$6.47M-$4.85M-$5.73M$25.78M$5.28M$7.52M-$12.00M$15.06M
Stock-based compensation$525.00K$556.00K$609.00K$611.00K$923.00K$858.00K$1.25M$1.40M$1.58M$1.60M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$25.00K$129.00K$177.00K$200.00K$200.00K$201.00K$719.00K$800.00K$800.00K$806.00K

Derived

Passage BIO, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Free cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio1.22x1.73x2.07x2.51x3.05x3.74x4.07x5.15x7.67x8.43x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open PASG in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-10View SEC filing
10-Q · Filed 2026-05-12View SEC filing
10-K · Filed 2026-03-03View SEC filing
10-Q · Filed 2025-11-10View SEC filing
10-Q · Filed 2025-08-12View SEC filing
10-Q · Filed 2025-05-13View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.